Edition:
United States

Biotechnology & Medical Research

Page 2

Neuroderm calls shareholders meeting to approve Mitsubishi Tanabe acquisition

Tuesday, 1 Aug 2017 04:05pm EDT

Aug 1 (Reuters) - Neuroderm Ltd :Neuroderm announces extraordinary general meeting of shareholders to approve acquisition by Mitsubishi Tanabe Pharma Corporation.

Safeguard Scientifics says its partner company, Good Start Genetics signed definitive agreement to be acquired By Invitae Corporation

Monday, 31 Jul 2017 05:16pm EDT

July 31 (Reuters) - Safeguard Scientifics Inc :Safeguard Scientifics Inc says its partner company, Good Start Genetics, Inc., signed definitive agreement to be acquired by Invitae Corporation.Safeguard Scientifics Inc - expects to receive initial consideration consisting $3.8 million Invitae stock,additional $1.3 million Invitae stock.

Loxo Oncology acquires BTK inhibitor program

Monday, 31 Jul 2017 06:45am EDT

July 31 (Reuters) - Loxo Oncology Inc :Loxo Oncology announces acquisition of highly selective, reversible BTK inhibitor program.Loxo Oncology Inc - ‍entered into a definitive agreement to purchase Bruton's Tyrosine Kinase inhibitor program from RedX Pharma PLC​.Loxo Oncology Inc - ‍under terms of agreement, Loxo Oncology has made a $40 million payment to RedX Pharma PLC for full acquisition of BTK discovery program​.Loxo Oncology Inc - ‍lead candidate from this program is expected to enter clinical development in 2018​.Loxo Oncology Inc - Loxo Oncology is not subject to milestone or royalty obligations.

Loxo Oncology acquires BTK inhibitor program

Monday, 31 Jul 2017 06:45am EDT

July 31 (Reuters) - Loxo Oncology Inc :Loxo Oncology announces acquisition of highly selective, reversible BTK inhibitor program.Loxo Oncology Inc - ‍entered into a definitive agreement to purchase Bruton's Tyrosine Kinase inhibitor program from RedX Pharma PLC​.Loxo Oncology Inc - ‍under terms of agreement, Loxo Oncology has made a $40 million payment to RedX Pharma PLC for full acquisition of BTK discovery program​.Loxo Oncology Inc - ‍lead candidate from this program is expected to enter clinical development in 2018​.Loxo Oncology Inc - Loxo Oncology is not subject to milestone or royalty obligations.

Icon acquires Mapi Group

Thursday, 27 Jul 2017 06:05am EDT

July 27 (Reuters) - Icon Plc ::Icon acquires Mapi Group.Icon Plc - has acquired Mapi Group.

Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement

Monday, 24 Jul 2017 07:00am EDT

July 24 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex.Expiration of Hart-Scott-Rodino act waiting period represents final regulatory closing condition required to complete asset purchase.Termination for pending sale of CTP-656 and other assets related to treatment of cystic fibrosis by Concert to Vertex Pharmaceuticals.

Concert Pharmaceuticals terminates Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement

Monday, 24 Jul 2017 07:00am EDT

July 24 (Reuters) - Concert Pharmaceuticals Inc :Concert Pharmaceuticals announces termination of the Hart-Scott-Rodino act waiting period for CTP-656 asset purchase agreement with Vertex.Expiration of Hart-Scott-Rodino act waiting period represents final regulatory closing condition required to complete asset purchase.Termination for pending sale of CTP-656 and other assets related to treatment of cystic fibrosis by Concert to Vertex Pharmaceuticals.

Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma for $1.1 bln

Monday, 24 Jul 2017 02:00am EDT

July 24 (Reuters) - Neuroderm Ltd :Neuroderm enters definitive agreement to be acquired by Mitsubishi Tanabe Pharma corporation for US$1.1 billion in cash.Mitsubishi Tanabe Pharma will acquire neuroderm for us$39 per share in cash.Neuroderm Ltd says currently anticipates transaction will close in Q4 of 2017.Neuroderm deal has received unanimous approval by board and implies an equity value of approximately us$1.1 billion.Special meeting of shareholders to approve transaction is expected to be held this fall.

Spain's Oryzon sees no impact of Roche decision on finances

Thursday, 20 Jul 2017 04:04am EDT

July 20 (Reuters) - Spain's Oryzon CEO Carlos Buesa::Says the decision by Roche <<>> to drop cancer drug will not have a short-, medium-term impact on Oryzon finances.Says: "The company's capacity to continue developing its business is stable from the financial point of view." .

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary